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What are the novel findings of this work?
Antenatal treatment for twin anemia–polycythemia
sequence (TAPS) differs considerably between fetal
therapy centers. The rate of perinatal mortality was
comparable following treatment of TAPS with expectant
management, laser surgery, intrauterine transfusion (IUT)
(with or without partial exchange transfusion (PET)),
delivery or selective feticide. Severe neonatal morbidity
was significantly higher in cases treated with IUT (± PET)
or delivery within 7 days after diagnosis. Prolongation of
pregnancy was best achieved by expectant management,
laser surgery and selective feticide.
What are the clinical implications of this work?
There is no international consensus on the optimal
management for TAPS. Treatment groups differed
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significantly at baseline, hampering reliability and
generalizability of our results. To improve the outcome
of TAPS pregnancies, a randomized controlled trial
investigating the best treatment option is urgently needed.
ABSTRACT
Objective To investigate the antenatal management and
outcome in a large international cohort of monochorionic
twin pregnancies with spontaneous or post-laser twin
anemia–polycythemia sequence (TAPS).
Methods This study analyzed data of monochorionic twin
pregnancies diagnosed antenatally with spontaneous or
post-laser TAPS in 17 fetal therapy centers, recorded in
the TAPS Registry between 2014 and 2019. Antenatal
diagnosis of TAPS was based on fetal middle cerebral
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artery peak systolic velocity > 1.5 multiples of the median
(MoM) in the TAPS donor and <1.0 MoM in the TAPS
recipient. The following antenatal management groups
were defined: expectant management, delivery within
7 days after diagnosis, intrauterine transfusion (IUT)
(with or without partial exchange transfusion (PET)),
laser surgery and selective feticide. Cases were assigned
to the management groups based on the first treatment
that was received after diagnosis of TAPS. The primary
outcomes were perinatal mortality and severe neonatal
morbidity. The secondary outcome was diagnosis-to-birth
interval.
Results In total, 370 monochorionic twin pregnancies
were diagnosed antenatally with TAPS during the study
period and included in the study. Of these, 31% (n = 113)
were managed expectantly, 30% (n = 110) with laser
surgery, 19% (n = 70) with IUT (± PET), 12% (n = 43)
with delivery, 8% (n = 30) with selective feticide and 1%
(n = 4) underwent termination of pregnancy. Perinatal
mortality occurred in 17% (39/225) of pregnancies in
the expectant-management group, 18% (38/215) in the
laser group, 18% (25/140) in the IUT (± PET) group,
10% (9/86) in the delivery group and in 7% (2/30) of
the cotwins in the selective-feticide group. The incidence
of severe neonatal morbidity was 49% (41/84) in the
delivery group, 46% (56/122) in the IUT (± PET) group,
31% (60/193) in the expectant-management group, 31%
(57/182) in the laser-surgery group and 25% (7/28) in the
selective-feticide group. Median diagnosis-to-birth inter-
val was longest after selective feticide (10.5 (interquartile
range (IQR), 4.2–14.9) weeks), followed by laser surgery
(9.7 (IQR, 6.6–12.7) weeks), expectant management
(7.8 (IQR, 3.8–14.4) weeks), IUT (± PET) (4.0 (IQR,
2.0–6.9) weeks) and delivery (0.3 (IQR, 0.0–0.5) weeks).
Treatment choice for TAPS varied greatly within and
between the 17 fetal therapy centers.
Conclusions Antenatal treatment for TAPS differs con-
siderably amongst fetal therapy centers. Perinatal mortal-
ity and morbidity were high in all management groups.
Prolongation of pregnancy was best achieved by expec-
tant management, treatment by laser surgery or selective
feticide. © 2020 The Authors. Ultrasound in Obstetrics
& Gynecology published by John Wiley & Sons Ltd
on behalf of the International Society of Ultrasound in
Obstetrics and Gynecology.
INTRODUCTION
Twin anemia–polycythemia sequence (TAPS) occurs as a
result of chronic unbalanced fetofetal transfusion through
minuscule placental anastomoses in monochorionic
twins, leading to anemia in the donor and polycythemia
in the recipient1. Unlike twin-to-twin transfusion syn-
drome (TTTS), TAPS develops in the absence of twin
oligohydramnios–polyhydramnios sequence (TOPS).
TAPS occurs spontaneously in 3–5% of monochorionic
twins and arises after incomplete laser surgery for TTTS
in 2–16% of cases, due to the presence of minuscule
residual anastomoses2,3.
TAPS is a relatively newly recognized condition,
first described in 20064. Since then, our knowledge
with respect to this condition has increased greatly
and insights into the pathophysiology, diagnosis and
outcome of TAPS have gradually been established5.
However, the best antenatal management for TAPS is
still unknown. Options include expectant management,
preterm delivery, intrauterine transfusion (IUT) in the
donor with or without partial exchange transfusion
(PET) in the recipient, fetoscopic laser surgery of the
placental vascular anastomoses and selective feticide.
Since TAPS is associated with high rates of adverse
short- and long-term outcomes, it is crucial to investigate
which management strategy offers TAPS twins the best
outcome6–8. Unfortunately, due to the low incidence
of the condition, studies are limited to small sample
sizes, thus hampering generalizability of the results and
necessitating caution when comparing the outcomes. To
generate more substantiated knowledge on the effects of
different management strategies for TAPS twins, we set up
the TAPS Registry, an international collaboration aimed
at collecting data on diagnosis, management and outcome
of pregnancies with TAPS.
The aim of the current study was to investigate the
perinatal outcome associated with different antenatal
management strategies in monochorionic twin pregnan-
cies with spontaneous or post-laser TAPS and to report
the antenatal management choices for TAPS in 17 fetal
therapy centers across the world.
METHODS
The TAPS Registry was established in 2014 as a
web-based registry for anonymous data collection on twin
pregnancies complicated by TAPS. Fetal therapy centers
across the world were invited to participate. Participating
centers were supplied with personal credentials to enter
data of their TAPS cases into the online registry. Between
2014 and 2019, a total of 17 centers contributed to data
collection (Appendix S1).
Inclusion criteria
Women were eligible for the study if they were pregnant
with monochorionic twins diagnosed with spontaneous or
post-laser TAPS. The diagnosis for TAPS was based on a
middle cerebral artery (MCA) peak systolic velocity (PSV)
discrepancy between the twins, defined as MCA-PSV
> 1.5 multiples of the median (MoM) in the TAPS
donor combined with MCA-PSV < 1.0 MoM in the TAPS
recipient, in the absence of TOPS9. Cases were excluded
if TAPS was diagnosed for the first time postnatally
(i.e. missed antenatally) and/or if they were diagnosed
with post-laser TAPS within 1 week after laser for TTTS,
unless TAPS persisted after 1 week, and/or if they were
first diagnosed with TAPS at Stage 5. The outcomes of
TAPS cases diagnosed postnatally are presented in two
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other studies investigating perinatal outcome separately
in spontaneous and post-laser TAPS10,11.
Collected information
Data on maternal characteristics, diagnosis, management,
delivery, placental injection studies and perinatal outcome
were collected. The following information was retrieved
from local medical records: gravidity, parity, location of
the placenta, time of diagnosis (antenatal or postnatal),
gestational age (GA) at diagnosis and TAPS stage at
diagnosis. In addition, the type of antenatal management
was recorded, including expectant management, preterm
delivery, IUT (± PET), fetoscopic laser surgery, selective
feticide or termination of pregnancy (TOP). For each
management decision, the GA and TAPS stage were
noted, as well as the indication. The severity of antenatal
TAPS was determined according to the staging system
by Slaghekke et al. published previously12. The following
delivery data were retrieved: type of delivery (spontaneous
or planned), mode of delivery (vaginal or Cesarean) and
type of Cesarean delivery (elective or emergency). Based
on placental color dye examination, the type, size and
number of placental anastomoses were recorded. Perinatal
outcome information collected included donor/recipient
status, hemoglobin and reticulocyte values, treatment with
blood transfusion for anemia or PET for polycythemia
on day 1, presence of severe neonatal morbidity and/or
severe cerebral injury, and occurrence of perinatal
mortality.
Management group allocation
We defined the following antenatal management groups
for TAPS: expectant management, delivery (defined as a
delivery within 7 days after diagnosis), IUT (± PET), laser
surgery and selective feticide. Since different management
strategies may be used in the same TAPS pregnancy,
management-group allocation was based on the first
strategy followed. The following rules were applied
for management-group allocation: cases were assigned
to the laser-surgery, IUT (± PET) or selective-feticide
group if that was the first treatment they received
within 14 days after diagnosis of TAPS (we allowed
a 1-week re-examination to confirm the diagnosis of
TAPS). If this treatment was performed after 14 days,
cases were included in the expectant-management group.
If cases received laser surgery combined with an IUT
during the same procedure, they were assigned to the
laser-surgery group. Cases with laser surgery in which
other interventions were needed to manage persisting
or recurrent TAPS, were assigned to the laser-surgery
group.
Population characteristics
For all management groups, the following parameters
were studied: type of TAPS (post-laser or spontaneous),
location of the placenta, GA at diagnosis, TAPS stage
at diagnosis, incidence of preterm prelabor rupture of
the membranes (PPROM), GA at PPROM, type of
delivery (spontaneous or planned), mode of delivery
(vaginal or Cesarean), GA at birth, presence of TAPS
postnatally, treatment for postnatal TAPS (defined as
blood transfusion in the donor and/or PET in the recipient
at birth) and number of survivors per pregnancy. The
postnatal diagnosis of TAPS was established in the
presence of intertwin hemoglobin difference > 8.0 g/dL
combined with at least one of the following: a reticulocyte
count ratio > 1.7 or presence of only minuscule vascular
anastomoses detected through color dye injection of the
placenta13,14. Furthermore, specific management-related
characteristics were evaluated for each management
group. For expectant management we investigated
spontaneous resolution of TAPS, defined as absence of
TAPS postnatally. In pregnancies managed with IUT
(± PET), the number of interventions, time interval
between interventions (in days) and site(s) of transfusion
were examined. In cases that underwent multiple IUT
(± PET) procedures, the median number of days between
interventions was used. In cases that underwent laser
surgery, we assessed recurrent/persistent TAPS, presence
of residual anastomoses (evaluated after birth using color
dye injection of the placental vessels) and delivery within
24 h after the procedure. In pregnancies treated with
selective feticide, donor/recipient status of the treated fetus
and the indication for selective feticide were evaluated. For
expectant management, IUT (± PET) and laser surgery,
any additional treatment after the initial intervention was
recorded.
Primary and secondary outcomes
The primary outcomes of this study were perinatal mor-
tality and severe neonatal morbidity. Secondary outcome
was diagnosis-to-birth interval. Outcomes were compared
between the different management groups (expectant
management, delivery, IUT (± PET), laser surgery and
selective feticide) in the total cohort and for spontaneous
and post-laser TAPS separately. Perinatal mortality was
defined as fetal demise or neonatal death within 28 days
after birth. In the selective-feticide group, perinatal mor-
tality was reported only for the cotwin. Severe neonatal
morbidity was defined as the presence of at least one
of the following, diagnosed within 28 days after birth or
before discharge to home: respiratory distress syndrome
requiring mechanical ventilation and surfactant, patent
ductus arteriosus requiring treatment, necrotizing entero-
colitis ≥ Stage 215, retinopathy of prematurity ≥ Stage 316,
amniotic band syndrome, ischemic limb injury or severe
cerebral injury. Severe cerebral injury was diagnosed in the
presence of one of the following abnormalities on cere-
bral imaging: intraventricular hemorrhage ≥ Stage 317,
ventricular dilatation (including post-hemorrhagic ven-
tricular dilatation)18, cystic periventricular leukomalacia
≥ Grade 219, porencephalic or parenchymal cysts, arterial
infarction or other severe cerebral lesions associated with
adverse outcome.
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Statistical analysis
Statistical analyses were carried out using SPSS Statistics
version 25.0 (IBM Corp., Armonk, NY, USA). Data are
presented as median and interquartile range (IQR) with
or without range (minimum–maximum), or n/N (%), as
appropriate. A P-value < 0.05 was considered statistically
significant. For comparison between treatment groups
of outcomes analyzed per pregnancy, one-way analysis
of variance (ANOVA) with Tukey correction was used
for comparison of continuous variables and a chi-square
test was used for comparison of categorical variables.
Comparison between groups of outcomes analyzed per
fetus or neonate was performed using the generalized
estimated equation (GEE) module to account for the fact
that observations between cotwins are not independent.
As a GEE cannot be used when an outcome event does not
occur in one of the groups, an adjustment to the data was
applied in such cases, according to which, an unaffected
child was changed into an affected child in all groups.
This correction generates more conservative P-values.
For the one-way ANOVA and GEE, the outcome in the
expectant-management group was set as the reference
value. When using the chi-square test, P-values are
reported for the comparison between all treatment groups.
RESULTS
Of the 422 TAPS cases that were entered in the TAPS
Registry between 2014 and 2019, 10% (n = 43) were
diagnosed postnatally and excluded from the present
study. Of the remaining 379 cases, eight were excluded
because post-laser TAPS was diagnosed within 1 week
after laser for TTTS but did not persist beyond the first
week, and one further case was excluded as it was TAPS
Stage 5 at antenatal diagnosis. Therefore, a total of 370
cases were included in the study. The number of cases
contributed by each fetal therapy center is presented
in Appendix S1. Antenatal management consisted of
expectant management in 31% (n = 113) of pregnancies,
laser surgery in 30% (n = 110), IUT (± PET) in 19%
(n = 70), delivery within 7 days after diagnosis in 12%
(n = 43), selective feticide in 8% (n = 30) and TOP in
1% (n = 4). Pregnancies that underwent TOP are not
considered further. Pregnancy and delivery characteristics
for each management group are presented in Table 1.
Expectant-management group
The median GA at diagnosis in the expectant man-
agement group was 22.6 (IQR, 19.9–27.1; range,
15.1–35.0) weeks. The median antenatal TAPS stage at
diagnosis was 2 (IQR, 1–2). The presence of TAPS at
birth could be evaluated in 98% (111/113) of the cases
managed expectantly. Spontaneous resolution was seen in
16% (18/111) of cases and occurred in 17% (9/52) with
TAPS Stage 1, 13% (6/45) with Stage 2, 18% (2/11) with
Stage 3 and 20% (1/5) with Stage 4. In 12% (13/113) of
cases, an alternative management strategy was performed
after 14 days of expectant management. IUT (± PET) was
elected in eight TAPS cases (after 15–97 days from diagno-
sis), based on progression of TAPS stage (n = 5), ongoing
Stage-1 TAPS (n = 2) and initial recovery followed by
recurrence of TAPS after 13 weeks (n = 1). In the other
five cases, laser surgery was performed for progression of
TAPS stage (after 15–38 days from diagnosis). In two of
the cases managed with laser surgery, delivery took place
within 24 h after the procedure, resulting in miscarriage
(23 weeks) in one case and premature (28 weeks) birth in
the other with double infant survival. In the other three
cases that underwent laser surgery, perinatal survival was
seen in 5/6 neonates.
Laser-surgery group
Initial management by laser surgery was performed
in 110 pregnancies at a median GA of 22.0 (IQR,
19.5–24.3; range, 16.7–30.1) weeks. Spontaneous TAPS
cases comprised the majority of this treatment group
(78%; 86/110). In total, 43% (47/110) of the TAPS
pregnancies treated with laser surgery had an anterior
placenta. Laser surgery was combined with an IUT in the
same procedure in 11% (12/110) of the pregnancies. In
4% (4/108) of cases treated with laser surgery, delivery
took place within 24 h after the procedure (at 21, 22, 24
and 28 weeks, respectively).
Recurrent TAPS was seen in 15% (16/106) of the
cases that underwent laser surgery. In one of these
cases, recurrent TAPS was diagnosed only postnatally.
Of the remaining 15 pregnancies, 20% (n = 3) were
managed expectantly, 33% (n = 5) with IUT (± PET),
13% (n = 2) with laser reintervention and 33% (n = 5)
with selective feticide. Of the three cases managed
expectantly, spontaneous resolution of TAPS was seen
in one, and in the other two, neonatal mortality occurred
in three of four liveborn infants. In the recurrent-TAPS
cases that were managed with IUT (± PET), fetal demise
of the donor occurred in two of the five twin pairs after the
first IUT. In both cases the cotwin survived. In the other
three cases, two or three IUT (± PET) interventions were
performed and all infants survived. In both pregnancies
with recurrent TAPS that had laser reintervention, the
procedure was successful resulting in perinatal survival
of the twins. Of the five recurrent-TAPS cases treated
with selective feticide, this was performed in the donor
twin in four and in the recipient twin in one. In one
case, fetal demise of the cotwin occurred. Aside from the
recurrent-TAPS cases, selective feticide was performed in
two additional cases treated with laser surgery, based on
severe cerebral injury in the donor detected after laser
intervention.
Postnatal TAPS was diagnosed in 9% (6/65) of liveborn
twin pairs treated with laser surgery. Placental injection
information was available in 33% (36/110) of pregnancies
treated with laser surgery. Residual anastomoses were
detected in 19% (7/36) of these and were minuscule in all
instances. All cases with residual anastomoses (7/7) had
recurrent TAPS.
© 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2020; 56: 378–387.
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
382 Tollenaar et al.
Table 1 Pregnancy and delivery characteristics of 366 monochorionic twin pregnancies diagnosed prenatally with twin anemia–
polycythemia sequence (TAPS), according to initial management strategy after diagnosis
Characteristic
Expectant management
(n = 113)
Laser surgery
(n = 110)
IUT (± PET)
(n = 70)
Delivery
(n = 43)
Selective feticide
(n = 30)
GA at diagnosis (weeks) 22.6 (19.9–27.1;
15.1–35.0)
21.7 (19.3–23.9;
16.1–28.9)
25.8 (23.3–28.0;
17.0–32.1)
31.3 (28.6–34.0;
26.0–35.0)
21.4 (19.1–22.9;
15.1–24.0)
GA at intervention (weeks) — 22.0 (19.5–24.3;
16.7–30.1)
26.3 (23.6–28.8;
18.0–32.1)
31.9 (29.1–34.1;
26.0–36.0)
22.1 (19.9–23.2;
17.1–24.6)
Spontaneous TAPS 51/113 (45) 86/110 (78) 26/70 (37) 34/43 (79) 19/30 (63)
Anterior placenta 55/113 (49) 47/110 (43) 42/70 (60) 22/43 (51) 19/30 (63)
TAPS stage at diagnosis 2 (1–2; 1–4) 2 (2–3; 1–4) 2 (1–2; 1–4) 1 (1–2; 1–4) 2 (2–3; 1–4)
1 52/113 (46) 25/110 (23) 18/70 (26) 23/43 (53) 5/30 (17)
2 45/113 (40) 51/110 (46) 37/70 (53) 13/43 (30) 12/30 (40)
3 11/113 (10) 27/110 (25) 10/70 (14) 5/43 (12) 11/30 (37)
4 5/113 (4) 7/110 (6) 5/70 (7) 2/43 (5) 2/30 (7)
Subsequent treatment 13/113 (12) 17/110 (16) 10/70 (14) — —
Expectant — 3/110 (3) — — —
IUT (± PET) 8/113 (7) 5/110 (5) — — —
Laser (reintervention) 5/113 (4) 2/110 (2) 3/70 (4) — —
Selective feticide — 7/110 (6) 7/70 (10) — —
PPROM 29/113 (26) 40/107 (37)a 17/69 (25)c 4/43 (9) 13/29 (45)c
GA at PPROM (weeks) 29.0 (25.1–31.3;
21.0–36.4)
29.7 (25.9–32.1;
16.9–35.9)a
29.0 (25.8–31.5;
17.7–34.0)c
29.3 (26.6–33.4;
26.2–34.2)
27.9 (24.8–31.6;
20.2–33.3)c
Spontaneous onset of delivery 43/113 (38) 60/106 (57)b 20/69 (29)c 3/43 (7) 24/29 (83)c
Cesarean delivery 69/113 (61) 80/106 (75)b 50/69 (72)c 38/43 (88) 13/29 (45)c
Data are presented as median (interquartile range; range) or n/N (%). Data missing for: athree pregnancies; bfour pregnancies (including
three with missing PPROM data); cone pregnancy missing PPROM and delivery data. GA, gestational age; IUT, intrauterine transfusion;
PET, partial exchange transfusion; PPROM, preterm prelabor rupture of membranes.
Intrauterine transfusion (with or without partial
exchange transfusion) group
Initial management by IUT with or without PET was
performed in 70 pregnancies at a median GA of 26.3
(IQR, 23.6–28.8; range, 18.0–32.1) weeks. The median
antenatal TAPS stage at diagnosis was 2 (IQR, 1–2).
IUT was combined with PET in the recipient in 21%
(15/70) of pregnancies. In total, 73% (51/70) of the cases
in the IUT (± PET) group had one intervention, 13%
(9/70) had two, 7% (5/70) had three, 6% (4/70) had four,
and 1% (1/70) had six interventions. The median time
between interventions was 13.0 (IQR, 8.6–16.8; range,
6.5–21.0) days. The transfusion site was intravenous only
in 70% (47/67), intraperitoneal only in 10% (7/67)
and combined in 19% (13/67) of cases. An alternative
management strategy was decided in 14% (10/70) of
the cases treated with IUT (± PET). Three cases were
treated with laser surgery, all within 1 week after the
first IUT and based on progressive or recurrent TAPS. Of
these, one laser procedure was complete and the other
two were incomplete and both had recurrent TAPS.
In seven cases treated with IUT (± PET), a selective
feticide in the TAPS donor was performed based on
recurrent or progressive TAPS (n = 5) or severe cerebral
injury (n = 2).
Delivery group
Delivery within 7 days after diagnosis of TAPS was
the management choice in 43 pregnancies and took
place at a median GA of 31.9 (IQR, 29.1–34.1; range,
26.0–36.0) weeks. The median antenatal TAPS stage
for cases treated with delivery was 1 (IQR, 1–2). In
total, 88% (38/43) of these pregnancies had a Cesarean
section.
Selective-feticide group
Selective feticide was the first management choice in
30 TAPS pregnancies and was performed at a median
GA of 22.1 (IQR: 19.9–23.2, range: 17.1–24.6) weeks.
Indications for selective feticide were TAPS alone (67%;
20/30) or TAPS with co-existing severe growth restriction
(10%; 3/30), severe cerebral injury (10%; 3/30) or
congenital anomalies (10%; 3/30). In one further case,
selective feticide was performed at request of the parents
(3%; 1/30). Selective feticide was performed in the
TAPS donor in 87% (26/30) of pregnancies in this
group.
Comparison of outcome between management groups
Outcome data for the whole study population accord-
ing to management strategy are presented in Table 2.
The incidence of perinatal mortality was similar fol-
lowing expectant management (17%; 39/225), laser
surgery (18%; 38/215), IUT (± PET) (18%; 25/140),
delivery (10%; 9/86), and selective feticide (7%; 2/30)
(smallest P-value = 0.177 (selective feticide vs expectant
management)). Severe neonatal morbidity was signifi-
cantly higher in TAPS twins that underwent delivery
within 7 days after diagnosis (49%; 41/84) and IUT
© 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2020; 56: 378–387.
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
Treatment and outcome in 370 TAPS twins 383
Table 2 Outcome of 366 monochorionic twin pregnancies diagnosed prenatally with twin anemia–polycythemia sequence (TAPS),
according to initial management strategy after diagnosis
Outcome
Expectant
management
(n = 113
pregnancies;
n = 226 fetuses)
Laser surgery
(n = 110
pregnancies;
n = 220 fetuses)
IUT (± PET)
(n = 70
pregnancies;
n = 140 fetuses)
Delivery
(n = 43
pregnancies;
n = 86 fetuses)
Selective feticide
(n = 30
pregnancies;
n = 30 cotwins) P
GA at birth (weeks) 33.0 (30.1–34.9) 31.8 (29.1–34.1)d 31.1 (28.3–33.0)†‡ 31.9 (29.1–34.1) 32.1 (27.7–34.8) < 0.001
Diagnosis-to-birth interval (weeks) 7.8 (3.8–14.4) 9.7 (6.6–12.7) 4.0 (2.0–6.9)‡ 0.3 (0–0.5)†‡ 10.5 (4.2–14.9) < 0.001
Perinatal mortality 39/225 (17)a 38/215 (18)d 25/140 (18) 9/86 (10) 2/30 (7)† 0.177
Fetal demise* 24/226 (11) 28/215 (13) 18/140 (13) 0/86 (0)†‡ 2/30 (7) 0.024
Neonatal mortality* 15/201 (7)a 10/187 (5)d 7/122 (6) 9/86 (10)† 0/28 (0) 0.280
Survivors
None 5/112 (4)a 8/107 (7)d 3/70 (4) 1/43 (2) 2/30 (7) 0.700
One 27/112 (24)a 20/107 (19)d 18/70 (26) 7/43 (16) 28/30 (93) < 0.001
Two* 80/112 (71)a 79/107 (74)d 49/70 (70) 35/43 (81) 0/30 (0) < 0.001
At least one 107/112 (96)a 99/107 (93)d 67/70 (96) 42/43 (98) 28/30 (93) 0.696
Severe neonatal morbidity 60/193 (31)b 57/182 (31)e 56/122 (46)‡ 41/84 (49)h†‡ 7/28 (25) 0.027
Severe cerebral injury* 10/193 (5)b 6/182 (3)e 13/122 (11)† 8/84 (10)h 0/28 (0) 0.098
Postnatal TAPS 66/89 (74) 6/65 (9) 36/51 (71) 36/43 (84) — < 0.001
BT or PET at birth for TAPS* 81/188 (43)c 13/171 (8)f† 60/118 (51)g 48/84 (57)h 0/23 (0)i < 0.001
Data are presented as median (interquartile range) or n/N (%). Data missing for: aone infant with unknown neonatal outcome; bnine infants
(one with unknown neonatal outcome, three that died shortly after birth and five with unknown neonatal morbidity); c14 infants (same as
‘b’ plus five cases with missing BT/PET data); dfive infants (three pregnancies) with missing outcome; e10 fetuses (same as ‘d’ plus five with
missing neonatal outcome); f21 infants (same as ‘e’ plus 11 with unknown BT/PET data); gfour infants with missing BT/PET data; htwo
infants that died shortly after birth; ifive cotwins with missing BT/PET data. For comparisons using one-way analysis of variance and
generalized estimated equation (all outcomes per fetus/neonate and continuous outcomes per pregnancy), expectant management was set as
reference. For comparisons using chi-square test (categorical outcomes per pregnancy), P-values are for comparison between all treatment
groups. *Statistical correction for non-occurring events was applied. †Smallest P-value, which is presented in P-value column. ‡Statistically
significant P-value. BT, blood transfusion; GA, gestational age; IUT, intrauterine transfusion; PET, partial exchange transfusion.
(± PET) (46%; 56/122) compared with those man-
aged expectantly (31%; 60/193), treated with laser
surgery (31%; 57/182) or selective feticide (25%; 7/28)
(smallest P-value = 0.027 (delivery vs expectant man-
agement)). Diagnosis-to-birth interval was 7.8 (IQR,
3.8–14.4) weeks in the expectant-management group,
9.7 (IQR, 6.6–12.7) weeks after laser surgery and 10.5
(IQR, 4.2–14.9) weeks after selective feticide, and was
significantly shorter in twins treated with delivery (0.3
(IQR, 0.0–0.5) weeks) and IUT (± PET) (4.0 (IQR,
2.0–6.9) weeks) (smallest P-value <0.001 (delivery vs
expectant management). The prevalence of postnatal
TAPS was similar following expectant management
(74%; 66/89), IUT (± PET) (71%; 36/51) and deliv-
ery (84%; 36/43), and it was significantly lower in
twins treated with laser surgery (9%; 6/65) (P< 0.001,
chi-square test). Outcome data according to management
strategy followed are presented separately for sponta-
neous TAPS and post-laser TAPS in Tables 3 and 4,
respectively.
Management choice in 17 fetal therapy centers
Figure S1 shows the management choices for TAPS
pregnancies amongst the 17 fetal therapy centers.
Overall, management varied considerably between the
centers. Some centers, such as Leiden University Medical
Center, Vittore Buzzi Children’s Hospital in Milan
and Mater Mothers’ Hospital in Brisbane, adopted a
more conservative approach and managed a considerable
number of cases expectantly. In contrast, St George’s
University Hospital in London, Necker-Enfants Malades
Hospital in Paris and Children’s Memorial Hermann
Hospital in Houston, opted for more invasive treatment
of TAPS cases, using laser treatment or selective feticide.
The University Medical Center Hamburg-Eppendorf
in Hamburg and Vall d’Hebron University Hospital
in Barcelona in general refrained from performing
in-utero interventions and managed the majority of cases
expectantly or with delivery. The remaining centers did
not show a remarkable trend or preference in management
of TAPS pregnancies and applied the different treatment
options alternately.
DISCUSSION
This is the first large international study investigating
the outcome of TAPS pregnancies following different
antenatal management strategies. We found that the
incidence of perinatal mortality and severe neonatal
morbidity was high in all treatment groups. Management
of TAPS varied considerably within and between fetal
therapy centers, reflecting the lack of international
consensus on the optimal management strategy for
this condition. This study presents new information on
treatment for TAPS, thereby providing a more detailed
context for management decisions and an enhanced
understanding of TAPS and the clinical implications of
each treatment strategy.
© 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2020; 56: 378–387.
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Table 3 Outcome of 216 monochorionic twin pregnancies diagnosed prenatally with spontaneous twin anemia–polycythemia sequence
(TAPS), according to initial management strategy after diagnosis
Variable
Expectant
management
(n = 51
pregnancies;
n = 102 fetuses)
Laser surgery
(n = 86
pregnancies;
n = 172 fetuses)
IUT (± PET)
(n = 26
pregnancies;
n = 52 fetuses)
Delivery
(n = 34
pregnancies;
n = 68 fetuses)
Selective feticide
(n = 19
pregnancies;
n = 19 cotwins) P
GA at birth (weeks) 33.6 (31.3–35.4) 31.9 (29.1–34.4) ‡ 31.3 (30.1–33.1) 32.2 (31.1–34.3) 30.6 (27.2–35.5)†‡ 0.024
Diagnosis-to-birth interval (weeks) 7.7 (2.5–15.4) 10.3 (6.7–14.0) 2.4 (1.3–5.3) ‡ 0.3 (0.0–0.8)†‡ 11.1 (3.6–16.3) < 0.001
Perinatal mortality 12/101 (12)a 26/168 (15)d 2/52 (4)† 5/68 (7) 2/19 (11) 0.118
Fetal demise* 5/102 (5) 20/168 (12)d 2/52 (4) 0/68 (0) 2/19 (11)† 0.104
Neonatal mortality* 7/96 (7)a 6/148 (4)d 0/50 (0)† 5/68 (7) 0/17 (0) 0.165
Survivors
None* 1/50 (2)a 5/84 (6)d 0/26 (0) 0/34 (0) 2/19 (11) 0.178
One 8/50 (16)a 16/84 (19)d 2/26 (8) 5/34 (15) 17/19 (89) < 0.001
Two* 41/50 (82)a 63/84 (75)d 24/26 (92) 29/34 (85) 0/19 (0) < 0.001
At least one 49/50 (98)a 79/84 (94)d 26/26 (100) 34/34 (100) 17/19 (89) 0.174
Severe neonatal morbidity 26/93 (28)b 45/145 (31)e 22/50 (44) 32/67 (48)g†‡ 4/17(24) 0.046
Severe cerebral injury* 2/93 (2)b 3/145 (2)e 4/50 (8)† 5/67 (7)g 0/17 (0) 0.099
Postnatal TAPS 31/46 (67) 4/51 (8) 17/24 (71) 28/34 (82) — < 0.001
BT or PET at birth for TAPS* 36/89 (40)c 9/135(7)f†‡ 27/50 (54) 40/67 (60)g‡ 0/13 (0)h < 0.001
Data are presented as median (interquartile range) or n/N (%). Data missing for: aone infant with unknown neonatal outcome; bfour infants
(one with unknown neonatal outcome, one that died shortly after birth and two with unknown neonatal morbidity); ceight infants (same as
‘b’ plus four with missing BT/PET data); dfour infants (two pregnancies) with unknown outcome; eseven infants (same as ‘d’ plus three with
unknown neonatal morbidity); f17 infants (same as ‘e’ plus 10 without BT/PET data); gone infant that died shortly after birth; hfour cotwins
with missing BT/PET data. For comparisons using one-way analysis of variance and generalized estimated equation (all outcomes per
fetus/neonate and continuous outcomes per pregnancy), expectant management was set as reference. For comparisons using chi-square test
(categorical outcomes per pregnancy), P-values are for comparison between all treatment groups. *Statistical correction for non-occurring
events was applied. †Smallest P-value, which is presented in P-value column. ‡Statistically significant P-value. BT, blood transfusion; GA,
gestational age; IUT, intrauterine transfusion; PET, partial exchange transfusion.
Table 4 Outcome of 150 monochorionic twin pregnancies diagnosed prenatally with post-laser twin anemia–polycythemia sequence
(TAPS), according to initial management strategy after diagnosis
Variable
Expectant
management
(n = 62
pregnancies;
n = 124 fetuses)
Laser
surgery
(n = 24
pregnancies;
n = 48 fetuses)
IUT (± PET)
(n = 44
pregnancies;
n = 88 fetuses)
Delivery
(n = 9
pregnancies;
n = 18 fetuses)
Selective
feticide
(n = 11
pregnancies;
n = 22 cotwins) P
GA at birth (weeks) 32.6 (29.4–34.6) 31.7 (29.1–33.7)c 29.9 (29.0–33.0)†‡ 29.0 (27.7–31.8) 32.6 (31.13–34.0) 0.027
Diagnosis-to-birth interval (weeks) 8.0 (4.7–14.3) 8.1 (5.9–11.4) 4.8 (2.5–8.9)‡ 0.3 (0.2–0.4)†‡ 10.4 (9.2–14.4) < 0.001
Perinatal mortality* 27/124 (22) 12/47 (26)c 23/88 (26) 4/18 (22) 0/11 (0)† 0.217
Fetal demise* 19/124 (15) 8/47 (17)c 16/88 (18) 0/18 (0)† 0/11 (0)† 0.268
Neonatal mortality* 8/105 (8) 4/39 (10)c 7/72 (10) 4/18 (22)†‡ 0/11 (0) 0.040
Survivors
None* 4/62 (6) 3/23 (13)c 3/44 (7) 1/9 (11) 0/11 (0) 0.692
One 19/62 (31) 4/23 (17)c 16/44 (36) 2/9 (22) 11/11 (100) < 0.001
Two* 39/62 (63) 16/23 (70)c 25/44 (57) 6/9 (67) 0/11 (0) 0.002
At least one 58/62 (94) 20/23 (87)c 41/44 (93) 8/9 (89) 11/11 (100) 0.692
Severe neonatal morbidity 34/100 (34)a 12/37 (32)d 34/72 (47) 9/17 (53)g† 3/11 (27) 0.158
Severe cerebral injury* 8/100 (8)a 3/37 (8)d 9/72 (13) 3/17 (18)g† 0/11 (0) 0.141
Postnatal TAPS 35/43 (81) 2/14 (14) 19/27 (70) 8/9 (89) — < 0.001
BT or PET at birth for TAPS* 45/99 (45)b 4/36 (11)e†‡ 33/68 (49)f 8/17 (47)g 0/10 (0)h 0.011
Data are presented as median (interquartile range) or n/N (%). Data missing for: afive infants (two that died shortly after birth and three with
unknown outcome); bsix infants (same as ‘a’ plus one with missing BT/PET data); cone infant with unknown outcome; dthree infants (one
with unknown outcome and two with unknown neonatal morbidity); efour infants (same as ‘d’ plus one with missing BT/PET data); ffour
neonates with unknown BT/PET data; gone infant that died shortly after birth; hone cotwin with missing BT/PET data. For comparisons
using one-way analysis of variance and generalized estimated equation (all outcomes per fetus/neonate and continuous outcomes per
pregnancy), expectant management was set as reference. For comparisons using chi-square test (categorical outcomes per pregnancy),
P-values are for comparison between all treatment groups. *Statistical correction for non-occurring events was applied. †Smallest
P-value, which is presented in P-value column. ‡Statistically significant P-value. BT, blood transfusion; GA, gestational age; IUT, intra-
uterine transfusion; PET, partial exchange transfusion.
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Perinatal outcome
Confirming findings from previous smaller studies20–22,
we found comparable perinatal mortality rates between
the different management strategies, in the total cohort as
well as for spontaneous and post-laser TAPS pregnancies
separately. Notably, perinatal mortality was substantially
higher in pregnancies with post-laser TAPS compared
with those with spontaneous TAPS in all management
groups, illustrating the impact of preceding TTTS on
the outcome of twins with post-laser TAPS. Severe
perinatal morbidity rates were high in all groups, but
were significantly increased in cases treated with IUT
(± PET) or delivery within 7 days after diagnosis. Notably,
TAPS twins managed with IUT (± PET) were delivered
at a significantly earlier gestation compared with all
other management groups, which is known to have
significant impact on short-term outcome10,11. However,
twins managed with delivery were born at a comparable
gestational age to that of twins treated with laser surgery,
which suggests that other factors might play a role. Our
results show that expectant management, laser surgery
and selective feticide are associated with a prolongation of
the pregnancy for 7–10 weeks after the diagnosis of TAPS.
Significant prolongation of TAPS pregnancy after laser
surgery was previously reported by Slaghekke et al.20. Our
study shows that TAPS cases treated with IUT (± PET)
had a significantly shorter diagnosis-to-birth interval.
Although gestation can be prolonged by reintervention
with IUT (± PET), the majority of TAPS cases had only
one intervention. A possible explanation could be that,
due to the relatively high GA at diagnosis, caregivers
preferred delivery with subsequent postnatal treatment
over continuous exposure to TAPS, as soon as an
acceptable gestation was achieved.
What is the optimal treatment for twin anemia–
polycythemia sequence?
Determining the optimal treatment option is crucial in
order to improve the outcome of TAPS pregnancies. Laser
surgery is the only management option that treats the
cause of TAPS and has been shown to drastically improve
outcome in TTTS23. However, laser treatment in TAPS
is technically more challenging than in TTTS, due to the
absence of TOPS, which may lead to reduced accessibility
and visibility of the placental surface. This can be
especially problematic in cases of an anterior placenta.
To optimize technical conditions, TOPS can be artificially
created with amnioinfusion in one sac and amniodrainage
of the other, but this requires more needle insertions and
might increase the risk of PPROM and premature birth.
In our cohort, PPROM occurred in 37% and delivery
within 24 h after the procedure in 4% of pregnancies
treated with laser surgery, which is comparable to findings
following laser for TTTS3. A second technical problem
is the minuscule size of TAPS anastomoses, which makes
harder their detection during the procedure. Indeed, our
data showed that TAPS recurred in 15% of cases treated
with laser surgery, which is more than twice as high as
the recurrence rate of TTTS after laser3. Moreover, we
have shown that residual anastomoses after laser for
TAPS always lead to recurrence of the disease. To prevent
residual anastomoses and to ensure coagulation of anas-
tomoses that cannot be visualized, the Solomon technique
might be of added value3. Nevertheless, the rate of
residual anastomoses following laser in our TAPS cohort
was comparable to the rate of residual anastomoses in
TTTS (both 19%)3, and 43% of cases treated with laser
had an anterior placenta, which shows that, despite the
practical limitations, laser surgery for TAPS is technically
feasible.
Our data show that, although a promising approach,
laser surgery does not seem to improve (nor deteriorate)
perinatal outcome when compared with expectant man-
agement. However, laser surgery was associated with a
high diagnosis-to-birth interval, especially in comparison
to treatment with IUT (± PET). As prematurity has a
profound impact on short- and long-term health in TAPS
twins, prolongation of pregnancy is of the utmost impor-
tance to improve outcome6,7,10,11. Notably, a comparable
prolongation of pregnancy was achieved with selective
feticide and expectant management. However, selective
feticide comes with a high price, as parents lose at least
one baby and healthy survival of the cotwin is not guar-
anteed. On the other hand, in expectant management,
prolongation of pregnancy likely results in continuous
exposure to the potential detrimental effects of TAPS,
as only 16% of cases showed spontaneous resolution.
As risk for perinatal mortality and morbidity increases
with increasing antenatal TAPS stage, definitive treatment
with laser might be the optimal intervention to improve
perinatal outcome for this condition11,24.
Strengths and limitations
This large, international multicenter study is the first
to evaluate treatment choices for TAPS across the
world, and provides valuable information for clinicians
on both treatment and subsequent fetal and neonatal
outcomes. Nevertheless, caution should be exercised
when drawing conclusions based on the results we
obtained. Due to the retrospective nature of this study,
management groups are very likely to be subject to
selection bias. The management groups differed in
terms of GA at diagnosis, severity of TAPS and type of
TAPS. Since higher TAPS stage and post-laser TAPS are
associated with poorer prognosis, these factors could
have influenced significantly the perinatal outcome10,11.
Moreover, long-term outcome was not investigated in this
study. Previous studies have shown that the detrimental
effects of TAPS are not limited to the perinatal period,
but also manifest later in life6,7. Therefore, the true
effect of management for TAPS can only be properly
investigated when TAPS cases are randomized between
treatment groups, when stratification for risk factors is
applied, and when long-term consequences are taken
into account.
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Conclusions
This study shows that there is extensive heterogeneity
in the management choice for TAPS, both within and
amongst fetal therapy centers. To improve outcome
of TAPS pregnancies and to generate an international
consensus on optimal management, a randomized
controlled trial is urgently needed. Recently, the TAPS
trial, an international multicenter open-label randomized
controlled trial comparing laser surgery with standard
care (expectant management, IUT (± PET), preterm
delivery) has started recruiting patients25.
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Appendix S1 Details of 17 centers that contributed to data collection and number of cases from each center
Figure S1 Antenatal management of pregnancies with TAPS in 17 fetal therapy centers. IUT (± PET),
intrauterine transfusion (with or without partial exchange transfusion).
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